Patent DE-102005005395-A1 (DE)
Title: New thiazolidinone compounds are polo-like kinase inhibitors, useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases and viral diseases
Inventor: SCHULZE VOLKER KLAUS
IPC: A61P35/00
Filed: 2005-02-03
Abstract: Thiazolidinone compounds (I) and their salts, solvates, hydrates, stereoisomers, diastereomers and enantiomers are new. Thiazolidinone compounds of formula (I) and their salts, solvates, hydrates, stereoisomers, diastereomers, and enantiomers are new. Q : (hetero)aryl; A, B 1>1-6C alkyl or 1-6-C alkoxy (both optionally substituted by halo, -OH, 2-9C heterocycloalkyl, -NR 3>R 4> or -CO(NR 3>)-M) (where the heterocycloalkyl contains N, O or S and optionally: interrupted by -(CO)-, -SO 2- or double bond in the ring; and the ring is optionally substituted by -CN, halo, halo substituted 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl, -COR 2> or -NR 3>R 4>), H, halo, -OH, -NH 2, -NO 2, NR 3>R 4>, -NR 3>(CO)-L, -NR 3>(CO)-NR 3>-L, -COR 2>, -CO(NR 3>)-M, -NR 3>(CS)NR 3>R 4>, -NR 3>SO 2-L, -SO 2-NR 3>R 4> or -SO 2(NR 3>)-M; L : 1-6C alkyl or heteroaryl (both optionally substituted by -OH, 1-6C hydroxyalkoxy, 1-6C alkoxyalkoxy, 2-6C heterocycloalkyl or -NR 3>R 4>, where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bond in the ring; and the ring is optionally substituted by -CN, halo, halo substituted 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl, -COR 2> or -NR 3>R 4>); M : 1-6C alkyl (optionally substituted by -NR 3>R 4> or 2-6C heterocycloalkyl), where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bond in the ring; and the ring is optionally substituted by -CN, halo, halo substituted 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl, -COR 2> or -NR 3>R 4>; either W 1>heteroaryl or 2-9C heterocycloalkyl, where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bonds in the ring; and X, Y 1>1-6C alkyl, aryl (both optionally substituted by halo, -OH, 1-6C alkoxy, 1-6C alkylthio or aryl), -COOR 5>, -CONR 3>R 4> or H; or W 1>+X+Y 1>3-6C cycloalkyl ring or 2-6C heterocycloalkyl ring, where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bonds in the ring; and the ring is optionally substituted by 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl or -NR 3>R 1>; R 1>1-4C alkyl, 3C-cycloalkyl, allyl or propargyl (all optionally substituted by -CN or halo); R 2>-OH, 1-6C alkyl, 1-6C alkoxy or -NR 3>R 4>; either R 3>, R 4>1-6C alkyl, 1-6C alkoxy, CO-(1-6C)-alkyl, aryl (all optionally substituted by halo, -OH, 2-6C heterocycloalkyl, 1-6C hydroxyalkoxy or -NR 3>R 4>) or H, where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bond in the ring; and 2-6C heterocycloalkyl ring substituted by -CN, halo, 1-6C alkyl, 1-6C hydroxyalkyl, 1-6C alkoxy, 3-6C cycloalkyl, -NR 3>R 4> or -CO-NR 3>R 4>; or R 3>R 4>2-6C heterocycloalkyl ring, where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bonds in the ring; and the ring optionally substituted by halo, 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl, 1-6C alkoxyalkyl, -CN, -OH or -NR 3>R 4>; and R 5>1-6C alkyl (optionally substituted by halo, -OH, 2-6C heterocycloalkyl, 1-6C hydroxyalkoxy or -NR 3>R 4>), where the heterocycloalkyl contains N, O or S and optionally interrupted by -(CO)-, -SO 2- or double bonds in the ring; and the ring optionally substituted by 1-6C alkyl, 3-6C cycloalkyl, 1-6C hydroxyalkyl, 1-6C alkoxyalkyl, -CN, -OH or -NR 3>R 4>. An independent claim is also included for an intermediate substituted heterocyclic compound of formula (II). R x>1-3C alkyl. [Image] [Image] ACTIVITY : Cytostatic; Immunosuppressive; Endocrine-Gen.; Cardiovascular-Gen.; Antimicrobial; Neuroprotective. MECHANISM OF ACTION : Polo-like kinase inhibitor.